Photonz - producing high purity EPA from algal fermentation

Photonz - producing high purity EPA from algal fermentation

Photonz Corporation is a biotechnology company producing the omega-3 fatty acid eicosapentaenoic acid (EPA) from its primary source, marine microalgae. EPA is a critical ingredient in regulated pharmaceutical products and medicinal foods addressing cardiovascular disease.

Globally there is significant demand for pharmaceuticals using EPA as an active ingredient and this demand is increasing rapidly. Currently, the majority of EPA is extracted from wild fish oil - a limited and variable secondary source at risk of collapse. Photonz bypasses fish oil and any associated contaminants and pollutants and produces EPA directly from a microalgal source through a unique fermentation process, which confers a number of advantages.

Photonz fermentation product PNZ0901, is produced using Photonz' proprietary algal fermentation technology which overcomes a number of obstacles previously encountered in continuous fermentation of microalgae.

The Company owns or controls seven patent families covering fermentation and purification of microalgal EPA.

News

  • Photonz receives $2.9 million R+D Grant

    Posted on Mar. 28, 2011

    Awarded under the TechNZ programme, the grant will enable the biotech company to undertake work that will, when completed, allow it to commence commercial production of the omega-3 fatty acid eicosapentaenoic acid (EPA) from marine micro-algae....read more
  • Photonz successfully transfers process to industrial scale

    Posted on Nov. 21 2011

    Photonz Corporation has achieved a major milestone on the path to commercially manufacturing, by fermentation, the high-value omega-3 fatty acid, EPA...read more
  • Photonz signs with Novasep

    Posted on Sep. 21 2011

    Biotech company Photonz Corporation has entered into a development agreement with Novasep, a world-class provider of purification technology...read more
Site by Jet Creative Studio